Patient description: The patient is a 35-year-old woman with myasthenia gravis, class IIa. She complains of diplopia and fatigue and weakness that affects mainly her upper limbs. She had a positive anti-AChR antibody test, and her single fiber electromyography (SFEMG) was positive. She takes pyridostigmine 60 mg three times a day. But she still has some symptoms that interfere with her job. She is a research coordinator and has 3 children. Her 70-year-old father has hypertension. She does not smoke or use illicit drugs. She drinks alcohol occasionally at social events. Her physical exam and lab studies were not remarkable for any other abnormalities. BP: 110/75 Hgb: 11 g/dl WBC: 8000 /mm3 Plt: 300000 /ml Creatinine: 0.5 mg/dl BUN: 10 mg/dl Beta hcg: negative for pregnancy

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Metastatic Colon Adenocarcinoma Metastatic Colorectal Adenocarcinoma Metastatic Microsatellite Stable Colorectal Carcinoma Metastatic Rectal Adenocarcinoma Stage III Colon Cancer Stage III Colorectal Cancer Stage III Rectal Cancer Stage IIIA Colon Cancer Stage IIIA Colorectal Cancer Stage IIIA Rectal Cancer Stage IIIB Colon Cancer Stage IIIB Colorectal Cancer Stage IIIB Rectal Cancer Stage IIIC Colon Cancer Stage IIIC Colorectal Cancer Stage IIIC Rectal Cancer Stage IV Colon Cancer Stage IV Colorectal Cancer Stage IV Rectal Cancer Stage IVA Colon Cancer Stage IVA Colorectal Cancer Stage IVA Rectal Cancer Stage IVB Colon Cancer Stage IVB Colorectal Cancer Stage IVB Rectal Cancer Stage IVC Colon Cancer Stage IVC Colorectal Cancer Stage IVC Rectal Cancer Participants must have histologically or cytologically confirmed diagnosis of adenocarcinoma of the colon or rectum, with clinical confirmation of unresectable and/or metastatic disease that is measurable according to Response Evaluation in Solid Tumors (RECIST 1.1) Confirmation of BRAFV600E tumor as detected from testing performed in a Clinical Laboratory Improvement Act (CLIA)-certified laboratory Confirmation of MSS status from testing performed in a CLIA-certified laboratory Prior treatment with at least one systemic chemotherapy regimen for mCRC, or recurrence/progression with development of unresectable or metastatic disease within 6 months of adjuvant chemotherapy for resected CRC Eastern Cooperative Oncology Group performance status (ECOG PS) =< 1 (Karnofsky >= 70%) Absolute neutrophil count (ANC) >= 1.0 x 10^9/L Hemoglobin (Hgb) >= 9 g/dL with or without transfusions Platelets (PLT) >= 100 x 10^9/L without transfusions Total bilirubin =< 1.5 x upper limit of normal (ULN) and < 2 mg/dL Note: Patients who have a total bilirubin level > 1.5 x ULN and/or have Gilbert's disease will be allowed if their direct bilirubin level is =< 0.5 mg/dl or ULN, whichever is higher  Concurrent corticosteroid therapy or concurrent use of any other immunosuppressive medication (corticosteroid use on study as a pre-medication for IV contrast allergies/reactions is allowed). Subjects who are receiving daily steroid replacement therapy (the equivalent of prednisone =< 10 mg daily) serve as an exception to this rule Prior immune checkpoint therapy including, but not limited to, an anti-PD-1, anti-PD-L1, anti-PD-L2, anti-CD137, or anti-cytotoxic T-lymphocyte-associated antigen-4 (CTLA-4) antibody, or any other prior immunotherapy agent administered with antineoplastic intent Prior B-raf (BRAF) or mitogen-activated extracellular kinase (MEK)-targeted therapy Known hypersensitivity or contraindication to any component of binimetinib or encorafenib or their excipients Prior allogeneic tissue/solid organ transplant Interstitial lung disease (ILD) or history of pneumonitis that has required oral or IV steroids Receipt of a live vaccine within 30 days prior to the first administration of study medication. Seasonal flu vaccines that do not contain a live virus are permitted History of a grade 3 or 4 allergic reaction attributed to humanized or human monoclonal antibody therapy Active infection requiring concurrent antibiotic use